Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. (Q45975074)

18 December 2017

title

Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. (English)

1 reference

18 December 2017

0 references

Young-Chul Chung

1

1 reference

18 December 2017

Chun-Rong Lee

2

1 reference

18 December 2017

Tae-Won Park

3

1 reference

18 December 2017

Keum-Hwa Yang

4

1 reference

18 December 2017

Ki-Won Kim

5

1 reference

18 December 2017

publication date

1 January 2009

1 reference

18 December 2017

World Journal of Biological Psychiatry

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

18 December 2017

volume

10

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

156-162

1 reference

18 December 2017

Neurocognitive and social functioning in schizophrenia and other diagnoses.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Another view of therapy for cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Physostigmine ameliorates the delusions of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Efficacy and tolerability of low-dose donepezil in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Backward masking performance in unaffected siblings of schizophrenic patients. Evidence for a vulnerability indicator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Antipsychotic drug effects on brain morphology in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Neuroleptics and the Natural Course of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

Is it possible to be schizophrenic yet neuropsychologically normal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701432551

10.1080/15622970701432551

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017